Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRAME mRNA-based cancer vaccine
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PRAME mRNA-based cancer vaccine is an investigational immunotherapy developed by Moderna in collaboration with Immatics. The vaccine utilizes messenger RNA (mRNA) technology to encode the PRAME (preferentially expressed antigen in melanoma) protein, a tumor-associated antigen frequently overexpressed in various solid tumors but with limited expression in normal tissues. By delivering the genetic instructions for PRAME, the vaccine aims to stimulate the patient's immune system to generate a robust T-cell response against cancer cells expressing the antigen. It is currently being evaluated in Phase 1 clinical trials as a combination therapy with Immatics' IMA203, a T-cell receptor engineered T-cell (TCR-T) therapy, to potentially enhance the expansion, persistence, and clinical efficacy of the adoptive cell transfer.
- Other names
- PRAME mRNA vaccineModerna PRAME mRNA vaccine
02
Targets
PRAME (Preferentially expressed antigen in melanoma)
Beyond the preview
Go deeper on PRAME mRNA-based cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRAME mRNA-based cancer vaccine.